Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Mirum Pharmaceuticals Stock Performance
MIRM Stock traded up $0.25 during midday trading on Friday, reaching $25.00. 293,868 shares of the company were exchanged, compared to its average volume of 224,527. Mirum Pharmaceuticals has a 1-year low of $12.82 and a 1-year high of $30.55. The stock's 50-day simple moving average is $22.77 and its 200 day simple moving average is $23.01. The company has a market cap of $795.88 million, a price-to-earnings ratio of -15.03 and a beta of 1.44.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.21. Mirum Pharmaceuticals had a negative net margin of 137.85% and a negative return on equity of 139.72%. The company had revenue of $17.48 million for the quarter, compared to analysts' expectations of $15.67 million. On average, research analysts anticipate that Mirum Pharmaceuticals will post -4.3 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on MIRM shares. HC Wainwright decreased their price target on shares of Mirum Pharmaceuticals from $69.00 to $63.00 and set a "buy" rating for the company in a research note on Thursday. SVB Leerink lifted their price target on shares of Mirum Pharmaceuticals from $50.00 to $52.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 24th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of "Buy" and an average price target of $50.60.
Insiders Place Their Bets
In other news, major shareholder James E. Flynn sold 38,478 shares of Mirum Pharmaceuticals stock in a transaction on Monday, June 6th. The shares were sold at an average price of $25.01, for a total value of $962,334.78. Following the transaction, the insider now directly owns 1,540,190 shares of the company's stock, valued at approximately $38,520,151.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 33.27% of the stock is owned by corporate insiders.